Methylphenidate Hydrochloride is a defined ionic salt form offering distinct advantages in pharmaceutical processing and performance over the free acid or base. The counter-ion in Methylphenidate Hydrochloride has been selected based on toxicological acceptability at daily intake levels achievable from the proposed dosage regimen, and compatibility with the drug product excipient matrix. Solid-state characterisation of Methylphenidate Hydrochloride includes polymorph screening, stability under accelerated conditions, and determination of hygroscopic behaviour that may affect powder processing, fill weight uniformity, and long-term chemical stability in the drug product.
ICH Q3A qualification thresholds for impurities in new drug substances require toxicological qualification of individual impurities of Methylphenidate Hydrochloride exceeding the reporting threshold (0.05% or 1 mg TDI, whichever is lower), identification threshold (0.10% or 2 mg TDI), and qualification threshold (0.15% or 2 mg TDI).
